DaVita Inc. research snapshot
DVA AI stock analysis currently reads DaVita as a scaled kidney dialysis provider with durable patient need, strong cash conversion, aggressive buybacks, and material leverage. At the July 8, 2026 data cutoff, DVA traded near $234.31, close to its 52-week high, after Q1 2026 revenue rose to $3.416 billion and management raised 2026 adjusted diluted EPS guidance to $14.10 to $15.20. The DVA AI stock forecast is scenario-based, not a precise prediction, because the investment case depends on dialysis treatment volumes, Medicare and commercial reimbursement, labor costs, leverage, buyback discipline, and whether the market still rewards earnings per share growth after a large rally.
Current price
$234.31
Market cap
$15.04 billion verified market cap
AI score
64 / 100
Rating
High-cash-flow dialysis operator with strong 2026 EPS guidance, heavy leverage, and policy-sensitive reimbursement risk
Trend status
Strong positive technical trend, above the 50-day and 200-day moving averages
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | DaVita provides life-sustaining dialysis and related kidney care services for chronic kidney failure patients, with recurring medical need and national operating scale. | High |
| Moat | Scale, clinic density, physician relationships, operational know-how, payer contracting, and regulatory complexity create barriers, but the moat is capped by reimbursement rules and patient access scrutiny. | Medium-high |
| Management | Javier Rodriguez has continued DaVita long-term capital allocation around operations, debt, and buybacks, but management quality must be judged against leverage, clinic execution, and whether repurchases remain value-accretive at elevated prices. | Medium |
| Financial trend | FY2025 revenue rose 6.46% to $13.643 billion, adjusted operating income reached $2.094 billion, and Q1 2026 revenue rose 5.96% year over year to $3.416 billion. | High |
| Valuation | At $234.31, DVA screens near 22x TTM EPS, 15x forward earnings, 1.09x sales, about 10x to 12x free cash flow depending on FCF per-share source, and a negative book value due to buybacks and leverage. | Medium-high |
| Technical trend | The chart is in a strong uptrend, with price above Investing.com moving averages of about $226.45 for the 50-day and $207.70 for the 200-day, while RSI near 55.13 is positive but not extreme. | Medium |
| Risk level | Key risks are Medicare and commercial reimbursement, labor inflation, clinical quality events, high debt, negative common equity, payer mix, treatment volume, regulatory review, and buybacks at rich prices. | Medium-high |
| AI confidence | Descriptive confidence is high because company releases and StockAnalysis align on the major facts. Forecast confidence is lower because reimbursement and capital allocation are hard to model. | High data confidence |
| Investment certainty | DVA has a durable service base and strong cash flow, but after the share-price rally the setup requires continued execution rather than a simple low-multiple value case. | Medium |
DVA AI stock forecast
The DVA AI stock forecast uses the $234.31 price reference, TTM EPS of $10.74, 64.20 million shares outstanding, raised 2026 adjusted diluted EPS guidance of $14.10 to $15.20, and a three-year scenario model. The mechanical model produced about $352.90 in a bullish case, $216.50 in a base case, and $101.30 in a bearish case. Because DaVita uses significant leverage and repurchases stock, the practical forecast range should be read as a risk framework, not a price promise.
$270 to $350
More likely if adjusted EPS moves toward or above the high end of 2026 guidance, free cash flow stays near $1.0 billion to $1.25 billion, reimbursement remains stable, labor pressure is contained, and buybacks continue without stretching leverage.
$200 to $245
More likely if treatment volumes and reimbursement improve slowly, adjusted EPS lands inside guidance, debt remains manageable, and the market values DaVita around the current analyst target area rather than expanding the multiple.
$100 to $160
More likely if reimbursement pressure rises, commercial mix weakens, labor costs or clinical costs accelerate, leverage tightens financial flexibility, or repurchases at high prices reduce future per-share value.
DVA AI technical analysis
DVA AI technical analysis is positive but sensitive to failed-breakout risk as of the July 8, 2026 cutoff. StockAnalysis showed a July 7 close of $234.31 and a 52-week range of $101.00 to $239.64, while Investing.com listed the 50-day moving average near $226.45, the 200-day moving average near $207.70, a 14-day RSI near 55.13, and a daily technical summary of Strong Buy. The setup is trend-friendly while DVA holds above the 50-day average, but the stock is close enough to its 52-week high that earnings or policy disappointment could matter quickly.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $234.31 | StockAnalysis listed the July 7, 2026 close at $234.31, with after-hours trading near $232.65. |
| Immediate support | $226 to $228 | This range brackets the 50-day moving average near $226.45 and is the first trend support zone. |
| Secondary support | $207 to $210 | The 200-day moving average near $207.70 is the larger trend reference if the rally loses momentum. |
| Major support | $193 to $201 | This zone overlaps the average analyst target near $193.71 and the median target near $201, where valuation debate may intensify. |
| Near resistance | $239 to $240 | This range overlaps the 52-week high area near $239.64. |
| Upper resistance | $270 to $300 | This is an extension zone that would likely require another earnings beat, stable reimbursement commentary, and sustained EPS guidance confidence. |
| Moving averages | 50-day near $226.45, 200-day near $207.70 | Price is above both averages, so trend status remains positive while those levels hold. |
| Momentum | RSI near 55.13 | Momentum is positive but not extremely overbought on the Investing.com daily reading. |
| Volume | 914,044 shares on July 7 | Volume confirmation matters because DVA can move sharply around earnings, reimbursement news, and analyst target changes. |
| Volatility | Watch Aug. 4, 2026 earnings | The next expected earnings date is the main scheduled catalyst after the July 8 data cutoff. |
| Invalidation | Close below $226, then below $208 | A sustained close below the 50-day average would weaken the short-term setup. A break below the 200-day average would challenge the broader trend. |
DVA AI trading strategy
The DVA AI trading strategy below is a rules-based research framework, not personal advice. It links the stock chart with reimbursement policy, treatment volume, cash flow, leverage, buybacks, adjusted EPS guidance, and valuation discipline.
Watch for DVA to hold above the $226 to $228 50-day moving-average zone and break above $239 to $240 with earnings confirmation, stable reimbursement commentary, and full-year adjusted EPS guidance still intact.
A failed breakout followed by a close below $226 should reduce trend confidence, especially if management signals weaker treatment volume, higher labor pressure, or reimbursement headwinds.
If DVA pulls back toward $200 to $210 without a cut to 2026 guidance or deterioration in free cash flow, compare the lower price with the base-case scenario and debt capacity.
Do not treat a lower price as automatically attractive if reimbursement pressure, debt costs, or repurchase discipline deteriorates at the same time.
Track U.S. dialysis treatment volume, revenue per treatment, patient care cost per treatment, adjusted operating income, adjusted EPS guidance, free cash flow, debt, leverage, buybacks, and Medicare reimbursement updates.
Position sizing should reflect that DVA is a regulated health care services company with high financial leverage, not a guaranteed defensive compounder.
Investment research summary
Patients, payers, hospitals, and health systems rely on DaVita for dialysis and kidney care delivery. Customers pay because dialysis is medically necessary, recurring, operationally complex, and difficult to replace at national scale.
DaVita moat sources include clinic density, care protocols, staff training, physician relationships, payer contracting, purchasing scale, and regulatory know-how. The moat is meaningful but not absolute because reimbursement policy and commercial payer negotiations can reset economics.
The thesis fails if reimbursement falls, patient care costs rise faster than rates, treatment volumes stagnate, commercial mix weakens, debt reduces flexibility, buybacks overpay, or quality and compliance issues damage the franchise.
Management has emphasized operational execution, cash generation, and share repurchases. The key judgment is whether capital allocation stays rational after a sharp share-price move and whether leverage remains acceptable if policy conditions worsen.
Kidney disease treatment is tied to aging, diabetes, hypertension, and chronic care demand. The long-term need is durable, but growth is not a pure volume story because mortality, treatment mix, home dialysis adoption, and reimbursement rules all shape economics.
At $234.31, DVA is no longer priced like a neglected value stock. Margin of safety depends on whether $14.10 to $15.20 of 2026 adjusted EPS converts to durable free cash flow while debt, reimbursement, and buyback risk stay controlled.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| DVA quote reference | $234.31 close on July 7, 2026, with a 52-week range of $101.00 to $239.64 | StockAnalysis DVA overview | July 8, 2026 |
| Market capitalization verification | $15.04 billion reported and $15.04 billion calculated from $234.31 x 64.20 million shares | Pineify financial_rigor.py and StockAnalysis DVA overview | July 8, 2026 |
| Shares outstanding | 64.20 million shares outstanding, down 14.33% year over year in the StockAnalysis share statistics | StockAnalysis DVA statistics | July 8, 2026 |
| FY2025 revenue | $13.643 billion consolidated revenue in the FY2025 company release, cross-checked against StockAnalysis FY2025 revenue of $13.643 billion | DaVita FY2025 results release | July 8, 2026 |
| FY2025 net income to common | $746.8 million net income attributable to DaVita common shareholders in the FY2025 company release, matching StockAnalysis FY2025 net income to common | DaVita FY2025 results release and StockAnalysis financials | July 8, 2026 |
| Q1 2026 results and guidance | $3.416 billion revenue, $482 million operating income, $2.87 diluted EPS, $140 million free cash flow, and 2026 adjusted diluted EPS guidance of $14.10 to $15.20 | DaVita Q1 2026 results release | July 8, 2026 |
| Cash and debt | $644.2 million cash and cash equivalents, $10.514 billion long-term debt, and $112.7 million current portion of long-term debt at March 31, 2026 | DaVita Q1 2026 balance sheet | July 8, 2026 |
| Valuation ratios | StockAnalysis listed 22.54x trailing PE, 15.34x forward PE, 1.09x sales, 10.08x price to free cash flow, 7.42x price to operating cash flow, and 9.88x EV to EBITDA | StockAnalysis DVA statistics | July 8, 2026 |
| Technical indicators | Investing.com listed 50-day moving average $226.45, 200-day moving average $207.70, 14-day RSI 55.126, and a daily Strong Buy technical summary | Investing.com DVA technical analysis | July 8, 2026 |
This DVA AI stock analysis is an informational research tool only and is not investment advice, tax advice, or a recommendation to buy or sell DaVita Inc. shares. Forecast scenarios are based on available public data as of July 8, 2026 and can be wrong if earnings, reimbursement policy, labor costs, treatment volume, debt, interest rates, or market conditions change.
